Mutations of mitochondrial DNA in atherosclerosis and atherosclerosis-related diseases

Current Pharmaceutical Design

Volumn 21, Issue 9, 2015, Pages 1158-1163

  Sobenin, Igor A ^a,b   Zhelankin, Andrey V ^a   Mitrofanov, Konstantin Y ^b   Sinyov, Vasily V ^a,b   Sazonova, Margarita A ^a,b   Postnov, Anton Y ^a   Orekhov, Alexander N ^b,c  

^a INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^b INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^c Institute for Atherosclerosis Research   (Russian Federation)

Author keywords

Atherogenesis; Atherosclerosis; Coronary heart disease; Heteroplasmy; Mitochondrial DNA; Mutations

Indexed keywords

MITOCHONDRIAL DNA;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; DIABETES MELLITUS; DISEASE ASSOCIATION; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MITOCHONDRIAL DNA DISORDER; MITOCHONDRIAL GENOME; MOLECULAR PATHOLOGY; PRIORITY JOURNAL; CORONARY ARTERY DISEASE; GENETIC PREDISPOSITION; GENETICS; MUTATION;

ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DNA, MITOCHONDRIAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MUTATION;

EID: 84925883176     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666141013133000     Document Type: Article

References (85)

1. Schwartz CJ, Valente AJ, Sprague EA. A modern view of atherogenesis. Am J Cardiol 1993; 71: 9B-14B.
2. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-25.
3. Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyörälä K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention. Atherosclerosis 1998; 140: 199-270.
4. John PA, Ioannidis MD. Prediction of cardiovascular disease outcomes and established cardiovascular risk factors by genome-wide association markers. Circ Cardiovasc Genet 2009; 2: 7-15.
5. Döring Y, Noels H, Weber C. The use of high-throughput technologies to investigate vascular inflammation and atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32: 182-95.
6. Sivapalaratnam S, Motazacker MM, Maiwald S, et al. Genomewide association studies in atherosclerosis. Curr Atheroscler Rep 2011; 13: 225-32.
7. Sobenin IA, Chistiakov DA, Bobryshev YV, Postnov AY, Orekhov AN. Mitochondrial mutations in atherosclerosis: new solutions in research and possible clinical applications. Curr Pharm Des 2013; 19: 5942-53.
8. Yu E, Mercer J, Bennett M. Mitochondria in vascular disease. Cardiovasc Res 2012; 95: 173-82.
9. Stary HC. Changes in the cells of atherosclerotic lesions as advanced lesions evolve in coronary arteries of children and young adults. In: Pathobiology of the Human Atherosclerotic Plaque. Glagov S, Newman WP, Scaffer SA, Eds. Springer, New York, 1990; 93-106.
10. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999; 340: 115-26.
11. Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature 2011; 473: 317-25.
12. Packard RR, Libby P. Inflammation in atherosclerosis: from vascular biology to biomarker discovery and risk prediction. Clin Chem 2008; 54: 24-38.
13. Benditt EP, Benditt JM. Evidence for a monoclonal origin of human atherosclerotic plaque. Proc Natl Acad Sci USA 1973; 70: 1753-56.
14. Murry CE, Gipaya CT, Bartosek T, Benditt EP, Schwartz SM. Monoclonality of smooth-muscle cells in human atherosclerosis. Am J Pathol 1997; 151: 697-706.
15. Chung LM, Schwartz SM, Murry CE. Clonal architecture of normal and atherosclerotic aorta. Am J Pathol 1998; 152: 913-23.
16. Schwartz SM, Murry CE. Proliferation and the monoclonal origins of atherosclerotic lesions. Annu Rev Med 1998; 49: 437-60.
17. De Flora S, Izzotti A, Randerath K, et al. DNA adducts and chronic degenerative disease. Pathogenetic relevance and implications in preventive medicine. Mutat Res 1996; 366: 197-238.
18. De Flora S, Izzotti A, Walsh A, et al. Molecular epidemiology of atherosclerosis. FASEB J 1997; 11: 1021-31.
19. Markowitz SD. Atherosclerosis, just another cancer? J Clin Invest 1997; 100: 2143-5.
20. Andreassi MG, Botto N, Colombo MG, Biagini A, Clerico A. Genetic instability and atherosclerosis: can somatic mutation account for the development of cardiovascular diseases? Environ Mol Mutagen 2000; 35: 265-9.
21. Ross JS, Stagliano NE, Donovan MJ, Breitbart RE, Ginsburg GS. Atherosclerosis and cancer: common molecular pathways of disease development and progression. Ann N Y Acad Sci 2001; 947: 271-92.
22. Izzotti A, Cartiglia C, Lewtas J, De Flora S. Increased DNA alterations in atherosclerotic lesions of individuals lacking the GSTM1 genotype. FASEB J 2001; 15: 752-7.
23. Li R, Folsom AR, Sharrett AR, Couper D, Bray M, Tyroler HA. Interaction of the glutathione S-transferase genes and cigarette smoking on risk of lower extremity arterial disease: the Atherosclerosis Risk in Communities (ARIC) study. Atherosclerosis 2001; 154: 729-38.
24. Weinberg RA, Hanahan D. The molecular patogeneis of cancer. In: Molecular Oncology. Bishop JM, Weinberg RA, Eds. Scientific American Inc., New York. 1996; 179-204.
25. Parkes JL, Cardell RR, Hubbard FC Jr, Hubbard D, Meltzer A, Penn A. Cultured human atherosclerotic plaque smooth-muscle cells retain transforming potential and display enhanced expression of the myc proto-oncogene. Am J Pathol 1991; 138: 765-75.
26. Kiaris H, Hatzistamou J, Spandidos DA. Instability at the H-ras minisatellite in human atherosclerotic plaques. Atherosclerosis 1996; 125: 47-51.
27. Guevara NV, Kim HS, Antonova EI, Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat Med 1999; 5: 335-9.
28. Tabas I. p53 and atherosclerosis. Circ Res 2001; 88: 747-9.
29. Goldstein I, Rotter V. Regulation of lipid metabolism by p53-fighting two villains with one sword. Trends Endocrinol Metab 2012; 23: 567-75.
30. Spandidos DA, Ergazaki M, Arvanitis D, Kiaris H. Microsatellite instability in human atherosclerotic plaques. Biochem Biophys Res Commun 1996; 220: 137-40.
31. Hatzistamou J, Kiaris H, Ergazaki M, Spandidos DA. Loss of heterozygosity and microsatellite instability in human atherosclerotic plaques. Biochem Biophys Res Commun 1996; 225: 186-90.
32. McCaffrey TA, Du B, Consigli S, et al. Genomic instability in the type II TGF-beta 1 receptor gene in atherosclerotic and restenotic vascular cells. J Clin Invest 1997; 100: 2182-8.
33. Clark KJ, Cary NR, Grace AA, Metcalfe JC. Microsatellite mutation of type II transforming growth factor-beta receptor is rare in atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001; 21: 555-9.
34. Grati FR, Ghilardi G, Sirchia SM, et al. Loss of heterozygosity of the NOS3 dinucleotide repeat marker in atherosclerotic plaques of human carotid arteries. Atherosclerosis 2001; 159: 261-7.
35. Miniati P, Sourvinos G, Michalodimitrakis M, Spandidos DA. Loss of heterozygosity on chromosomes 1, 2, 8, 9 and 17 in cerebral atherosclerotic plaques. Int J Biol Markers 2001; 16: 167-71.
36. Fiotti N, Altamura N, Fisicaro M, Carraro N, Uxa L, Grassi G, et al. MMP-9 microsatellite polymorphism and susceptibility to carotid arteries atherosclerosis. Arterioscler Thromb Vasc Biol 2006; 26: 1330-6.
37. Andreassi MG, Botto N. DNA damage as a new emerging risk factor in atherosclerosis. Trends Cardiovasc Med 2003; 13: 270-5.
38. Dandona S, Roberts R. Genomic view of factors leading to plaque instability. Curr Cardiol Rep 2009; 11: 282-7.
39. Van Schooten FJ, Hirvonen LM, Maas BA, et al. Putative susceptibility markers of coronary artery disease-association between VDR genotype, smoking, and aromatic DNA adduct levels in human right atrial tissue. FASEB J 1998; 12: 1409-17.
40. Binkova B, Smerhovsky Z, Strejc P, et al. DNA-adducts and atherosclerosis: a study of accidental and sudden death males in the Czech Republic. Mutat Res 2002; 501: 15-28.
41. Botto N, Rizza A, Colombo MG, et al. Evidence for DNA damage in patients with coronary artery disease. Mutat Res 2001; 493: 23-30.
42. Lee SH, Blair IA. Oxidative DNA damage and cardiovascular disease. Trends Cardiovasc Med 2001; . 11: 148-55.
43. Borghini A, Cervelli T, Galli A, Andreassi MG. DNA modifications in atherosclerosis: from the past to the future. Atherosclerosis 2013; 230: 202-9.
44. Chistiakov DA, Sobenin IA, Revin VV, Orekhov AN, Bobryshev YV. Mitochondrial aging and age-related dysfunction of mitochondria. Biomed Res Int 2014; 2014: 238463.
45. Malik Q, Herbert KE. Oxidative and non-oxidative DNA damage and cardiovascular disease. Free Radic Res 2012; 46: 554-64.
46. Schon EA, Bonilla E, DiMauro S. Mitochondrial DNA mutations and pathogenesis. J Bioenerget Biomembr 1997; 29: 131-49.
47. Wallace DC. Mitochondrial DNA mutations in disease and aging. Environ Mol Mutagen 2010; 51: 440-50.
48. Sazonova M, Budnikov E, Khasanova Z, Sobenin I, Postnov A, Orekhov A. Studies of the human aortic intima by a direct quantitative assay of mutant alleles in the mitochondrial genome. Atherosclerosis 2009; 204: 184-90.
49. Sobenin IA, Sazonova MA, Postnov AY, Bobryshev YV, Orekhov AN. Changes of mitochondria in atherosclerosis: Possible determinant in the pathogenesis of the disease. Atherosclerosis 2013; 227: 283-8.
50. Sobenin IA, Sazonova MA, Postnov AY, Bobryshev YV, Orekhov AN. Mitochondrial mutations are associated with atherosclerotic lesions in the human aorta. Clin Dev Immunol 2012; 2012: 832464.
51. Botto N, Berti S, Manfredi S, et al. Detection of mtDNA with 4977 bp deletion in blood cells and atherosclerotic lesions of patients with coronary artery disease. Mutat Res 2005; 570: 81-8.
52. Mercer JR, Cheng KK, Figg N, et al. DNA damage links mitochondrial dysfunction to atherosclerosis and the metabolic syndrome. Circ Res 2011; 107: 1021-31.
53. Fujimoto H, Kobayashi H, Ohno M. Age-induced reduction in mitochondrial manganese superoxide dismutase activity and tolerance of macrophages against apoptosis induced by oxidized low density lipoprotein. Circ J 2010; 74: 353-60.
54. Tatarkova Z, Kuka S, Racay P, et al. Effects of aging on activities of mitochondrial electron transport chain complexes and oxidative damage in rat heart. Physiol Res 2011; 60: 281-9.
55. Nomiyama T, Tanaka Y, Piao L, et al. Accumulation of somatic mutation in mitochondrial DNA and atherosclerosis in diabetic patients. Ann N Y Acad Sci 2004; 1011: 193-204.
56. Mueller EE, Eder W, Ebner S, et al. The mitochondrial T16189C polymorphism is associated with coronary artery disease in Middle European populations. PLoS One 2011; 6: e16455.
57. Sobenin IA, Sazonova MA, Ivanova MM, et al. Mutation C3256T of mitochondrial genome in white blood cells: novel genetic marker of atherosclerosis and coronary heart disease. PLoS One 2012; 7: e46573.
58. Sobenin IA, Sazonova MA, Postnov AY, Salonen JT, Bobryshev YV, Orekhov AN. Association of mitochondrial genetic variation with carotid atherosclerosis. PLoS One 2013; 8: e68070.
59. Jaksch M, Ogilvie I, Yao J, et al. Mutations in SCO2 are associated with a distinct form of hypertrophic cardiomyopathy and cytochrome c oxidase deficiency. Hum Mol Genet 2000; 9: 795-801.
60. Jaksch M, Horvath R, Horn N, et al. Homozygosity (E140K) in SCO2 causes delayed infantile onset of cardiomyopathy and neuropathy. Neurology 2001; 57: 1440-6.
61. Lu J, Qian Y, Li Z, et al. Mitochondrial haplotypes may modulate the phenotypic manifestation of the deafness-associated 12S rRNA 1555A>G mutation. Mitochondrion 2010; 10: 69-81.
62. Singh R, Ellard S, Hattersley A, Harries LW. Rapid and sensitive real-time polymerase chain reaction method for detection and quantification of 3243A>G mitochondrial point mutation. J Mol Diagn 2006; 8: 225-30.
63. Löwik MM, Hol FA, Steenbergen EJ, Wetzels JF, van den Heuvel LP. Mitochondrial tRNALeu(UUR) mutation in a patient with steroid-resistant nephrotic syndrome and focal segmental glomerulosclerosis. Nephrol Dial Transplant 2005; 20; 336-41.
64. Nomiyama T, Tanaka Y, Piao L, et al. Accumulation of somatic mutation in mitochondrial DNA and atherosclerosis in diabetic patients. Ann N Y Acad Sci 2004; 1011: 193-204.
65. Reardon W, Ross RJ, Sweeney MG, et al. Diabetes mellitus associated with a pathogenic point mutation in mitochondrial DNA. Lancet 1992; 340: 1376-9.
66. Wong LJ, Senadheera D. Direct detection of multiple point mutations in mitochondrial DNA. Clin Chem 1997; 43: 1857-61.
67. Jeppesen TD, Schwartz M, Hansen K, Danielsen ER, Wibrand F, Vissing J. Late onset of stroke-like episode associated with a 3256C->T point mutation of mitochondrial DNA. J Neurol Sci 2003; 214: 17-20.
68. Kong QP, Bandelt HJ, Sun C, et al. Updating the East Asian mtDNA phylogeny: a prerequisite for the identification of pathogenic mutations. Hum Mol Genet 2006; 15: 2076-86.
69. Fu K, Hartlen R, Johns T, Genge A, Karpati G, Shoubridge EA. A novel heteroplasmic tRNAleu(CUN) mtDNA point mutation in a sporadic patient with mitochondrial encephalomyopathy segregates rapidly in skeletal muscle and suggests an approach to therapy. Hum Mol Genet 1996; 5: 1835-40.
70. Chol M, Lebon S, Bénit P, et al. The mitochondrial DNA G13513A MELAS mutation in the NADH dehydrogenase 5 gene is a frequent cause of Leigh-like syndrome with isolated complex I deficiency. J Med Genet 2003; 40: 188-91.
71. Shanske S, Coku J, Lu J, et al. The G13513A mutation in the ND5 gene of mitochondrial DNA as a common cause of MELAS or Leigh syndrome: evidence from 12 cases. Arch Neurol 2008; 65: 368-72.
72. Li Z, Liu Y, Yang L, Wang S, Guan MX. Maternally inherited hypertension is associated with the mitochondrial tRNA(Ile) A4295G mutation in a Chinese family. Biochem Biophys Res Commun 2008; 367: 906-11.
73. Li R, Liu Y, Li Z, Yang L, Wang S, Guan MX. Failures in mitochondrial tRNAMet and tRNAGln metabolism caused by the novel 4401A>G mutation are involved in essential hypertension in a Han Chinese family. Hypertension 2009; 54: 329.
74. Liu Y, Li R, Li Z, et al. Mitochondrial transfer RNAMet 4435A>G mutation is associated with maternally inherited hypertension in a Chinese pedigree. Hypertension 2009; 53: 1083-90.
75. Sobenin IA, Chistiakov DA, Sazonova MA, et al. Association of the level of heteroplasmy of the 15059G>A mutation in the MTCYB mitochondrial gene with essential hypertension. World J Cardiol 2013; 5: 132-40.
76. Wu LL, Chiou CC, Chang PY, Wu JT. Urinary 8-OHdG: a marker of oxidative stress to DNA and a risk factor for cancer, atherosclerosis and diabetics. Clin Chim Acta 2004; 339: 1-9.
77. Wang YC, Lee WC, Liao SC, et al. Mitochondrial DNA copy number correlates with oxidative stress and predicts mortality in nondiabetic hemodialysis patients. J Nephrol 2011; 24: 351-8.
78. Liu CS, Kuo CL, Cheng WL, Huang CS, Lee CF, Wei YH. Alteration of the copy number of mitochondrial DNA in leukocytes of patients with hyperlipidemia. Ann N Y Acad Sci 2005; 1042: 70-5.
79. Davidson SM, Duchen MR. Endothelial mitochondria: contributing to vascular function and disease. Circ Res 2007; 100: 1128-41.
80. Kennedy SR, Salk JJ, Schmitt MW, Loeb LA. Ultra-sensitive sequencing reveals an age-related increase in somatic mitochondrial mutations that are inconsistent with oxidative damage. PLoS Genet 2013; 9: e1003794.
81. Galkina E, Ley K. Immune and inflammatory mechanisms of atherosclerosis. Annu Rev Immunol 2009; 27: 165-97.
82. Diehl AM, Hoek JB. Mitochondrial uncoupling: role of uncoupling protein anion carriers and relationship to thermogenesis and weight control “the benefits of losing control.” J Bioenerg Biomembr 1999; 31: 493-506.
83. Kowald A, Kirkwood TB. Mitochondrial mutations, cellular instability and ageing: modeling the population dynamics of mitochondria. Mutat Res 1993; 295: 93-103.
84. Schapira AH. Mitochondrial diseases. Lancet 2012; 379: 1825-34.
85. Smith PM, Lightowlers RN. Altering the balance between healthy and mutated mitochondrial DNA. J Inherit Metab Dis 2011; 34: 309-13.